Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110720 | 1.00 | CYP1A1 (0.41) | CYP1A1CYP1A2CYP1B1F2RL3POLB | |
| SCHEMBL17531152 | 0.80 | POLB (0.43) | CYP1A1CYP1A2CYP1B1POLBL3MBTL1 | |
| SCHEMBL31393644 | 0.78 | F2RL3 (0.42) | CYP1A2F2RL3POLBL3MBTL1LMNA | |
| SCHEMBL21076531 | 0.78 | F2RL3 (0.39) | F2RL3POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL8269242 | 0.77 | MET (0.44) | CYP1A1CYP1A2CYP1B1KMT2AHTR2A | |
| SCHEMBL29210400 | 0.77 | F2RL3 (0.47) | F2RL3POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL21076479 | 0.77 | F2RL3 (0.39) | F2RL3HTR2AHTR2C | |
| SCHEMBL22490021 | 0.74 | HTR2A (0.37) | CYP1A1CYP1A2CYP1B1ALDH1A1NPC1 | |
| SCHEMBL18678557 | 0.74 | CYP2A6 (0.42) | F2RL3POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL15349692 | 0.74 | ALDH1A1 (0.51) | F2RL3POLBL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667259-A | Condensed ring compounds for inhibiting H-PGDS | 佐藤制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2955185-B1 | POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF | SHANGHAI FOSUN PHARMACEUTICAL DEV CO LTD (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2018029288-A1 | SULFONYL PYRIDYL TRP INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-02-15 | — | — | WO | disclosed |
| US-9550792-B2 | Polycyclic substituted pyrazole kinase activity inhibitors and use thereof | SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20150368259-A1 | Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof | SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2015-12-24 | — | — | US | disclosed |
| EP-2955185-A1 | POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF | China Pharmaceutical University (CN) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368259-A1 | Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof | MAP3K5, MAP3K19, MAP3K3 | CYP1A1 2515/4885CYP1A2 1733/4885CYP1B1 1840/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | CYP1A1 250/4885CYP1A2 160/4885CYP1B1 393/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | CYP1A1 327/4885CYP1A2 438/4885CYP1B1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.